Morphine Sulfate 20 mg/mL Intravenous Infusion is a compounded medication designed for end-of-life hospice care.
An intravenous bag is a sterile container used to administer customized compounded medications directly into a patient's bloodstream, providing precise and controlled treatment.

Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Morphine Sulfate 20 mg/mL Intravenous Infusion is a potent opioid analgesic formulation specifically designed for use in end-of-life hospice care. This formulation is delivered through an intravenous bag, a sterile container that ensures the appropriate administration of the medication directly into the patient's bloodstream. This method of delivery allows for rapid onset of action, providing immediate relief from severe pain and discomfort, which is crucial in managing symptoms associated with terminal illnesses.
The primary purpose of this formulation is to alleviate pain and improve the quality of life for patients in hospice care. Morphine sulfate works by binding to opioid receptors in the brain and spinal cord, altering the perception of pain and emotional response to it. Additionally, morphine sulfate can help alleviate other distressing symptoms such as dyspnea, which is common in end-of-life scenarios.
For prescribers, it is essential to consider the patient's overall condition, including their level of consciousness, respiratory function, and previous opioid use, when determining the appropriate dosage and infusion rate. The 20 mg/mL concentration allows for flexibility in dosing, enabling healthcare providers to tailor the treatment to the individual needs of the patient. It is crucial to monitor the patient closely for any signs of adverse effects, such as respiratory depression, sedation, or hypotension, and adjust the dosage accordingly.
Patients and their families should be informed about the purpose of this medication and its role in providing comfort during the end-of-life phase. Understanding the potential side effects and the importance of communication with healthcare providers can help in managing expectations and ensuring the patient's comfort and dignity are maintained.
At Bayview Pharmacy, we are committed to providing high-quality compounded medications tailored to the specific needs of our patients. If you have any questions or require further information about Morphine Sulfate 20 mg/mL Intravenous Infusion or any other formulations, please do not hesitate to reach out to us. Our team of experienced compounding pharmacists is here to assist you with any inquiries or concerns you may have.
Morphine Sulfate 20 mg/mL Intravenous Infusion is a potent opioid analgesic used primarily in end-of-life hospice care to manage severe pain and improve the quality of life for patients. Understanding these interactions is essential for both patients and prescribers to ensure optimal treatment outcomes.
Concomitant use of Morphine Sulfate with other central nervous system (CNS) depressants, such as benzodiazepines, barbiturates, or other opioids, can result in additive CNS depression. This may lead to profound sedation, respiratory depression, coma, or even death. It is important to closely monitor patients receiving these combinations and adjust dosages accordingly to minimize risks.
Patients taking monoamine oxidase inhibitors (MAOIs) or those who have recently discontinued MAOIs should exercise caution when using Morphine Sulfate. The combination can lead to unpredictable and severe reactions, including serotonin syndrome, characterized by symptoms such as agitation, hallucinations, rapid heart rate, and increased body temperature. A minimum of 14 days should elapse between discontinuation of MAOIs and initiation of Morphine Sulfate therapy.
Concomitant use of Morphine Sulfate with serotonergic drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), or tricyclic antidepressants, may increase the risk of serotonin syndrome. Patients should be monitored for symptoms of serotonin syndrome, and if they occur, discontinuation of the serotonergic drug or morphine should be considered.
Cytochrome P450 enzyme interactions can also affect the metabolism of Morphine Sulfate. Inhibitors of CYP3A4, such as certain antifungal agents (e.g., ketoconazole) and macrolide antibiotics (e.g., erythromycin), can increase morphine plasma concentrations, potentially leading to enhanced or prolonged opioid effects. Conversely, inducers of CYP3A4, such as rifampin and certain anticonvulsants (e.g., carbamazepine), may decrease morphine plasma concentrations, reducing its efficacy. Dose adjustments may be necessary when these agents are co-administered.
Alcohol consumption should be avoided while receiving Morphine Sulfate Infusion, as it can potentiate the sedative and respiratory depressant effects of morphine, increasing the risk of adverse outcomes. Patients should be advised to abstain from alcohol and consult their healthcare provider if they have any concerns.
In patients with renal or hepatic impairment, the clearance of morphine may be reduced, leading to increased plasma concentrations and prolonged effects. Careful monitoring and potential dose adjustments are recommended in these populations to avoid toxicity.
For patients and prescribers considering the use of Morphine Sulfate 20 mg/mL Intravenous Infusion, it is essential to review the patient's current medication regimen and medical history to identify potential interactions. This proactive approach can help mitigate risks and ensure the safe and appropriate use of this formulation in managing pain in end-of-life hospice care. If you have any questions or require further information, please reach out to us at Bayview Pharmacy.
Morphine Sulfate 20 mg/mL Intravenous Infusion is a potent opioid analgesic formulation specifically designed for administration via an intravenous bag, which is a sterile container used to deliver medications directly into a patient's bloodstream. This method of delivery ensures that the medication is rapidly absorbed and distributed throughout the body. The intravenous route is particularly beneficial in end-of-life hospice care, where managing severe pain and ensuring patient comfort are of utmost importance.
In the context of hospice care, Morphine Sulfate works by binding to opioid receptors in the brain and spinal cord, which are part of the central nervous system. These receptors are involved in the transmission of pain signals. By binding to these receptors, morphine effectively blocks the transmission of pain signals, thereby reducing the perception of pain. This mechanism of action not only alleviates physical discomfort but also helps in reducing the emotional distress associated with severe pain, which is crucial in providing comprehensive palliative care.
The formulation of Morphine Sulfate at a concentration of 20 mg/mL allows for precise dosing adjustments tailored to the individual needs of the patient. This is particularly important in hospice care, where patients may have varying levels of pain and different responses to opioid medications. The ability to customize the dosage ensures that each patient receives the optimal amount of medication necessary to manage their pain effectively, without causing excessive sedation or other adverse effects.
For prescribers, it is essential to consider the patient's overall condition, including their renal and hepatic function, as these can affect the metabolism and clearance of morphine. Regular monitoring and assessment are crucial to ensure that the patient is receiving the appropriate dose and to make any necessary adjustments. Additionally, prescribers should be aware of potential side effects, such as respiratory depression, constipation, and nausea, and manage these proactively to maintain the patient's quality of life.
For patients and their families, understanding how Morphine Sulfate works can provide reassurance that the medication is being used to maximize comfort and minimize suffering during end-of-life care. It is important to communicate openly with healthcare providers about any concerns or questions regarding the treatment plan, as this can help in achieving the best possible outcomes for the patient.
If you have any questions or need further information about Morphine Sulfate 20 mg/mL Intravenous Infusion or its use in hospice care, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of knowledgeable compounding pharmacists is here to assist you with any inquiries you may have.
Morphine sulfate 20 mg/mL intravenous infusion in an intravenous bag is primarily utilized for pain management in end-of-life hospice care, providing significant relief and comfort to patients dealing with chronic, severe pain. However, there are additional therapeutic uses of this formulation beyond hospice-specific scenarios. Its use may also extend to managing breakthrough pain in patients who are already on a regular pain medication regimen, ensuring that sudden and severe pain spikes are quickly controlled, enhancing the patient's overall quality of life.
For patients with severe burns or extensive trauma, this formulation acts as a central component of multimodal pain management strategies, assisting in the reduction of pain while enabling healthcare providers to stabilize the patient's condition. Additionally, in palliative care settings beyond hospice, morphine sulfate intravenous infusions can be critical in managing symptoms associated with organ failure or progressive diseases, providing relief from both pain and associated discomforts, such as dyspnea. In emergency medicine, morphine infusion may be employed for the immediate relief of severe, acute pain resulting from heart attacks or accidents, as it not only alleviates pain but also elicits a calming effect, aiding in reducing the anxiety that often accompanies sudden medical emergencies.
Prescribers should evaluate each patient's individual needs, considering factors such as previous opioid exposure, current medication regimen, and overall health status, before initiating treatment with this formulation. The titration should be carefully managed to balance efficacy with the minimization of potential side effects, such as respiratory depression, which requires vigilant monitoring. Patients and caretakers should be informed about the purpose of this medication, expected outcomes, and potential side effects to ensure appropriate and safe usage. Our pharmacy team encourages both patients and healthcare professionals to reach out with any questions or concerns regarding the use of this formulation, as we are committed to supporting optimal healthcare outcomes through tailored medication solutions.
Morphine Sulfate 20 mg/mL Intravenous Infusion is used in hospice care to manage severe pain in patients who are nearing the end of life. It provides relief by acting on the central nervous system to alleviate discomfort.
This medication is administered intravenously, meaning it is delivered directly into a patient's bloodstream through an IV bag, ensuring precise and controlled treatment.
The intravenous bag allows for the sterile, precise, and efficient delivery of morphine directly into the bloodstream, offering quicker pain relief and better control over dosing.
Yes, the IV bags should be stored in a cool, dry place and away from direct sunlight. Follow the specific storage instructions provided by the pharmacy or healthcare provider.
Common side effects include drowsiness, dizziness, or nausea. If severe or unusual side effects occur, such as trouble breathing or a rapid heartbeat, seek medical attention immediately.
Morphine Sulfate works by binding to opioid receptors in the brain and spinal cord, reducing the perception of pain and altering the emotional response to pain.
Yes, the healthcare provider will tailor the dosage based on the patient’s specific needs, taking into account factors like pain severity, response to treatment, and tolerance levels.
In some cases, and under medical supervision, this medication may be administered at home by a trained caregiver or through the support of hospice care services.
Yes, patients receiving Morphine Sulfate require careful monitoring for effectiveness of pain relief and potential side effects, which should be managed by healthcare professionals.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
The conditions listed on this page are indications prescribers have ordered this preparation for. They are not FDA-approved indications, and listing them is not a statement that this preparation is effective for them.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice — discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.